OABI logo

OmniAb (OABI) Company Overview

Profile

Full Name:

OmniAb, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

September 30, 2021

Indexes:

Not included

Description:

OmniAb (OABI) is a biotechnology company that focuses on developing and providing innovative antibody discovery solutions. They use advanced technologies to create high-quality antibodies for research and therapeutic applications, helping scientists and companies in drug development and disease treatment.

Key Details

Price

$3.61

Annual Revenue

$34.16 M(-42.17% YoY)

Annual EPS

-$0.51(-96.15% YoY)

Annual ROE

-15.43%

Beta

1.07

Events Calendar

Earnings

Next earnings date:

Mar 20, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 20, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Nov 14, 24 HC Wainwright & Co.
Buy
Nov 14, 24 Benchmark
Buy
Aug 19, 24 Benchmark
Buy
Aug 16, 24 RBC Capital
Outperform
Aug 12, 24 HC Wainwright & Co.
Buy
May 14, 24 Benchmark
Buy
Mar 26, 24 Truist Securities
Buy
Mar 22, 24 Benchmark
Buy
Mar 21, 24 RBC Capital
Outperform
Mar 21, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

OmniAb to Participate in Two Investor Conferences in March
OmniAb to Participate in Two Investor Conferences in March
OmniAb to Participate in Two Investor Conferences in March
OABI
businesswire.comFebruary 3, 2025

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of March. TD Cowen 45th Annual Health Care Conference, March 3-5 at the Boston Marriott Copley Place. Management will be presenting a corporate overview on Tuesday, March 4th at 2:30 p.m. Eastern time and will be holding one-on-one meetings with investors. 2025 Leerink Partners Global Healthcare Conference, March 9-12 at the W Hotel.

Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law Firm
OABI
prnewswire.comJanuary 31, 2025

NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of OmniAb, Inc. (NASDAQ: OABI) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference
OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference
OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference
OABI
businesswire.comDecember 16, 2024

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that two presentations featuring the Company's technologies were delivered at the 2024 Antibody Engineering & Therapeutics Conference (AETC) underway in San Diego. In a presentation titled “Building Multispecifics from in vivo Derived Antibody Domains and Alternative Scaffolds,” Yasmina Abdiche, Ph.D., Vice President of Exploratory Research, provided an overview of building multispecifics ranging from tradition.

OmniAb, Inc. (OABI) Reports Q3 Loss, Lags Revenue Estimates
OmniAb, Inc. (OABI) Reports Q3 Loss, Lags Revenue Estimates
OmniAb, Inc. (OABI) Reports Q3 Loss, Lags Revenue Estimates
OABI
zacks.comNovember 12, 2024

OmniAb, Inc. (OABI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.16 per share a year ago.

OmniAb, Inc. (OABI) Q2 2024 Earnings Call Transcript
OmniAb, Inc. (OABI) Q2 2024 Earnings Call Transcript
OmniAb, Inc. (OABI) Q2 2024 Earnings Call Transcript
OABI
seekingalpha.comAugust 10, 2024

OmniAb, Inc. (NASDAQ:OABI ) Q2 2024 Earnings Call August 8, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President and Chief Executive Officer Conference Call Participants Michael Sonntag - Leerink Partners Chad Wiatrowski - TD Cowen Stephen Willey - Stifel Conor McNamara - RBC Capital Markets Operator Good afternoon and welcome to OmniAb Incorporated 2024 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

OmniAb to Participate in the Jefferies Global Healthcare Conference
OmniAb to Participate in the Jefferies Global Healthcare Conference
OmniAb to Participate in the Jefferies Global Healthcare Conference
OABI
businesswire.comMay 20, 2024

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating at the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City. Management will be presenting a corporate overview on Wednesday, June 5th at 8:00 a.m. Eastern time and will be holding one-on-one meetings with investors. A live and archived webcast of the presentation will be available in the Investors section of OmniAb's websit.

OmniAb, Inc. (OABI) Q4 2023 Earnings Call Transcript
OmniAb, Inc. (OABI) Q4 2023 Earnings Call Transcript
OmniAb, Inc. (OABI) Q4 2023 Earnings Call Transcript
OABI
Seeking AlphaMarch 20, 2024

OmniAb, Inc. (OABI) Q4 2023 Earnings Call Transcript

OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?
OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?
OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?
OABI
Zacks Investment ResearchFebruary 28, 2024

OmniAb, Inc. (OABI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

OmniAb: Hold For Growth
OmniAb: Hold For Growth
OmniAb: Hold For Growth
OABI
Seeking AlphaSeptember 25, 2023

OmniAb is a long-term growth story. The company's Q2 earnings call reported nice growth in its projects and partners. As a newly formed company with lumpy revenues and limited liquidity, OmniAb still has work to do to support a bull thesis.

OmniAb, Inc. (OABI) Q2 2023 Earnings Call Transcript
OmniAb, Inc. (OABI) Q2 2023 Earnings Call Transcript
OmniAb, Inc. (OABI) Q2 2023 Earnings Call Transcript
OABI
Seeking AlphaAugust 12, 2023

OmniAb, Inc. (NASDAQ:OABI ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Kurt Gustafson - CFO Matthew Foehr - President, CEO Conference Call Participants Puneet Souda - Leerink Partners Robyn Karnauskas - Truist Securities Stephen Willey - Stifel Jack Siedow - Craig-Hallum Chad Wiatrowski - TD Cowen Brandon Carney - B.Riley Operator Good afternoon, and welcome to OmniAb, Inc. Second Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for OmniAb?
  • Does OmniAb pay dividends?
  • What sector is OmniAb in?
  • What industry is OmniAb in?
  • What country is OmniAb based in?
  • When did OmniAb go public?
  • Is OmniAb in the S&P 500?
  • Is OmniAb in the NASDAQ 100?
  • Is OmniAb in the Dow Jones?
  • When was OmniAb's last earnings report?
  • When does OmniAb report earnings?
  • Should I buy OmniAb stock now?

What is the ticker symbol for OmniAb?

The ticker symbol for OmniAb is NASDAQ:OABI

Does OmniAb pay dividends?

No, OmniAb does not pay dividends

What sector is OmniAb in?

OmniAb is in the Healthcare sector

What industry is OmniAb in?

OmniAb is in the Biotechnology industry

What country is OmniAb based in?

OmniAb is headquartered in United States

When did OmniAb go public?

OmniAb's initial public offering (IPO) was on September 30, 2021

Is OmniAb in the S&P 500?

No, OmniAb is not included in the S&P 500 index

Is OmniAb in the NASDAQ 100?

No, OmniAb is not included in the NASDAQ 100 index

Is OmniAb in the Dow Jones?

No, OmniAb is not included in the Dow Jones index

When was OmniAb's last earnings report?

OmniAb's most recent earnings report was on Nov 12, 2024

When does OmniAb report earnings?

The next expected earnings date for OmniAb is Mar 20, 2025

Should I buy OmniAb stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions